First evaluation of PET-based human biodistribution and dosimetry of 18F-FAZA, a tracer for imaging tumor hypoxia
A Savi, E Incerti, F Fallanca, V Bettinardi… - Journal of Nuclear …, 2017 - Soc Nuclear Med
18F-labeled fluoroazomycinarabinoside (18F-FAZA) is a PET biomarker for noninvasive
identification of regional tumor hypoxia. The aim of the present phase I study was to evaluate …
identification of regional tumor hypoxia. The aim of the present phase I study was to evaluate …
Multiparametric analysis of the relationship between tumor hypoxia and perfusion with 18F-fluoroazomycin arabinoside and 15O-H2O PET
R Iqbal, GM Kramer, EE Verwer… - Journal of Nuclear …, 2016 - Soc Nuclear Med
18F-fluoroazomycin arabinoside (18F-FAZA) is a PET tracer of tumor hypoxia. However, as
hypoxia often is associated with decreased perfusion, the delivery of 18F-FAZA may be …
hypoxia often is associated with decreased perfusion, the delivery of 18F-FAZA may be …
PET imaging of tumor hypoxia using 18F-fluoroazomycin arabinoside in stage III–IV non–small cell lung cancer patients
VR Bollineni, GSMA Kerner, J Pruim… - Journal of Nuclear …, 2013 - Soc Nuclear Med
Tumor hypoxia hampers the efficacy of radiotherapy because of its increased resistance to
ionizing radiation. The aim of the present study was to estimate the potential added clinical …
ionizing radiation. The aim of the present study was to estimate the potential added clinical …
[HTML][HTML] Significant impact of different oxygen breathing conditions on noninvasive in vivo tumor-hypoxia imaging using [18 F]-fluoro-azomycinarabino-furanoside ([18 …
FC Maier, M Kneilling, G Reischl, F Cay, D Bukala… - Radiation …, 2011 - Springer
Background [18 F] FAZA is a PET biomarker with great potential for imaging tumor hypoxia.
Aim of our study was to compare [18 F] FAZA uptake in mice with subcutaneous exogenous …
Aim of our study was to compare [18 F] FAZA uptake in mice with subcutaneous exogenous …
Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside
M Piert, HJ Machulla, M Picchio, G Reischl… - Journal of Nuclear …, 2005 - Soc Nuclear Med
The study was performed to compare the 18F-labeled nitroimidazole compound
fluoroazomycin arabinoside (18F-FAZA) with the standard hypoxia tracer fluoromisonidazole …
fluoroazomycin arabinoside (18F-FAZA) with the standard hypoxia tracer fluoromisonidazole …
Parametric methods for quantification of 18F-FAZA kinetics in non–small cell lung cancer patients
EE Verwer, I Bahce, FHP van Velden… - Journal of Nuclear …, 2014 - Soc Nuclear Med
18F-fluoroazomycinarabinoside (18F-FAZA) is a hypoxia-specific PET tracer. In future
clinical applications of hypoxia imaging, such as early response monitoring or radiation …
clinical applications of hypoxia imaging, such as early response monitoring or radiation …
[HTML][HTML] [18F]EF3 is not superior to [18F]FMISO for PET-based hypoxia evaluation as measured in a rat rhabdomyosarcoma tumour model
L Dubois, W Landuyt, L Cloetens, A Bol… - European journal of …, 2009 - Springer
Purpose The aim of this investigation was to quantitatively compare the novel positron
emission tomography (PET) hypoxia marker 2-(2-nitroimidazol-1-yl)-N-(3 [18 F], 3, 3 …
emission tomography (PET) hypoxia marker 2-(2-nitroimidazol-1-yl)-N-(3 [18 F], 3, 3 …
[HTML][HTML] Biodistribution and radiation dosimetry of the novel hypoxia PET probe [18F]DiFA and comparison with [18F]FMISO
S Watanabe, T Shiga, K Hirata, K Magota, S Okamoto… - EJNMMI research, 2019 - Springer
Background To facilitate hypoxia imaging in a clinical setting, we developed 1-(2, 2-
dihydroxymethyl-3-[18 F]-fluoropropyl)-2-nitroimidazole ([18 F] DiFA) as a new tracer that …
dihydroxymethyl-3-[18 F]-fluoropropyl)-2-nitroimidazole ([18 F] DiFA) as a new tracer that …
[HTML][HTML] A comparative study of the hypoxia PET tracers [18F] HX4,[18F] FAZA, and [18F] FMISO in a preclinical tumor model
SGJA Peeters, CML Zegers, NG Lieuwes… - International Journal of …, 2015 - Elsevier
Purpose Several individual clinical and preclinical studies have shown the possibility of
evaluating tumor hypoxia by using noninvasive positron emission tomography (PET). The …
evaluating tumor hypoxia by using noninvasive positron emission tomography (PET). The …
Pharmacokinetic analysis of [18F]FAZA in non-small cell lung cancer patients
EE Verwer, FHP van Velden, I Bahce, M Yaqub… - European journal of …, 2013 - Springer
Abstract Purpose [18 F] Fluoroazomycin arabinoside (FAZA) is a positron emission
tomography (PET) tracer developed to enable identification of hypoxic regions within a …
tomography (PET) tracer developed to enable identification of hypoxic regions within a …